# Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)

> **NCT05091411** · PHASE3 · UNKNOWN · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 1680 (estimated)

## Conditions studied

- Coronavirus Disease 2019

## Interventions

- **BIOLOGICAL:** Recombinant new coronavirus vaccine (CHO cell) group

## Key facts

- **NCT ID:** NCT05091411
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-09
- **Primary completion:** 2021-11
- **Final completion:** 2022-12
- **Target enrollment:** 1680 (ESTIMATED)
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05091411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05091411, "Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05091411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*